Literature DB >> 14596689

Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.

Heather DeGrendele.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14596689     DOI： 10.1016/S1525-7304(11)70324-2

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  4 in total

1.  Ultrasound-promoted synthesis and immunosuppressive activity of novel quinazoline derivatives.

Authors:  Lei Zhang; Zhe Gao; Chen Peng; Zheng-Yang Bin; Dan Zhao; Jing Wu; Qiang Xu; Jian-Xin Li
Journal:  Mol Divers       Date:  2012-08-14       Impact factor: 2.943

2.  EGFR-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells.

Authors:  Tomohisa Yokoyama; Justina Tam; Shinji Kuroda; Ailing W Scott; Jesse Aaron; Tim Larson; Manish Shanker; Arlene M Correa; Seiji Kondo; Jack A Roth; Konstantin Sokolov; Rajagopal Ramesh
Journal:  PLoS One       Date:  2011-11-07       Impact factor: 3.240

3.  EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage.

Authors:  Shinji Kuroda; Justina Tam; Jack A Roth; Konstantin Sokolov; Rajagopal Ramesh
Journal:  Int J Nanomedicine       Date:  2014-08-08

4.  Gene Co-Expression Analysis Predicts Genetic Variants Associated with Drug Responsiveness in Lung Cancer.

Authors:  Sanaya Shroff; Jie Zhang; Kun Huang
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2016-07-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.